Volume 16, Issue 5 (Sep-Oct 2022)                   mljgoums 2022, 16(5): 37-42 | Back to browse issues page

XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

zeinali P, saghaeian M, Asadi J, Jafari S M. High Dose of 3, 7-Dimethyl-1-Propargylxanthine Induces Cell Death in YM-1 and KYSE30 Cancer Cell Lines. mljgoums. 2022; 16 (5) :37-42
URL: http://mlj.goums.ac.ir/article-1-1496-en.html
1- Department of Biochemistry and Biophysics, School of Medicine, Golestan University of Medical Sciences, Gorgan, Iran
2- Metabolic Disorders Research Center, Golestan University of Medical Sciences, Gorgan, Iran
3- Metabolic Disorders Research Center, Golestan University if Medical Sciences, Gorgan, Iran
4- Metabolic Disorders Research Center, Golestan University if Medical Sciences, Gorgan, Iran , s.meh.jafari@goums.ac.ir
Abstract:   (108 Views)
Background and objectives: Activation of adenosine A2a receptor has been shown to induce the growth and metastasis of cancer cells. The role of this receptor in esophageal cancer has not yet been determined. The present study aimed to investigate effects of an adenosine A2a receptor antagonist (3, 7-dimethyl-1-propargylxanthine) on growth of esophageal cancer cells.
Methods: Real-time polymerase chain reaction was performed to evaluate mRNA expression of the A2a adenosine receptor in KYSE-30 and YM-1 esophageal cancer cell lines. Effects of the antagonist on viability of the cells were evaluated by MTT assay.
Results: At low concentrations, the antagonist had no effect on cell viability. However, at concentrations ≥200 μM, the antagonist significantly reduced viability of both cell lines (p<0.05).
Conclusion: The results of this study indicate that the adenosine A2a receptor antagonist exerts inhibitory effects on KYSE30 and YM-1 cancer cells in a dose-dependent manner. Therefore, the use of this antagonist can be exploited as a therapeutic target for the treatment of esophageal cancer.
Full-Text [PDF 519 kb]   (34 Downloads) |   |   Full-Text (HTML)  (20 Views)  
Research Article: Research Article | Subject: Biochemistry
Received: 2022/03/11 | Accepted: 2022/04/30 | Published: 2022/09/6 | ePublished: 2022/09/6

References
1. Zhang Y. Epidemiology of esophageal cancer. World journal of gastroenterology: WJG. 2013; 19(34): 5598. [View at Publisher] [DOI:10.3748/wjg.v19.i34.5598] [PubMed] [Google Scholar]
2. Sheikh M, Poustchi H, Pourshams A, Etemadi A, Islami F, Khoshnia M, et al. Individual and combined effects of environmental risk factors for esophageal cancer based on results from the Golestan Cohort Study. Gastroenterology. 2019;156(5):1416-27. [View at Publisher] [DOI:10.1053/j.gastro.2018.12.024] [PubMed] [Google Scholar]
3. Masters GA, Krilov L, Bailey HH, Brose MS, Burstein H, Diller LR, et al. Clinical cancer advances 2015: annual report on progress against cancer from the American Society of Clinical Oncology. Journal of Clinical Oncology. 2015; 33(7): 786-809. [DOI:10.1200/JCO.2014.59.9746] [PubMed] [Google Scholar]
4. Rowinsky EK. Signal events: cell signal transduction and its inhibition in cancer. The Oncologist. 2003; 8(S3): 5-17. [DOI:10.1634/theoncologist.8-suppl_3-5] [PubMed] [Google Scholar]
5. Burnstock G, Verkhratsky A. Receptors for purines and pyrimidines. Purinergic Signalling and the Nervous System: Springer. 2012; 119-244. [View at Publisher] [DOI:10.1007/978-3-642-28863-0_5] [Google Scholar]
6. Fredholm BB, IJzerman AP, Jacobson KA, Linden J, Müller CE. International :union: of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors-an update. Pharmacological reviews. 2011;63(1):1-34. [DOI:10.1124/pr.110.003285] [PubMed] [Google Scholar]
7. Kazemi MH, Raoofi Mohseni S, Hojjat‐Farsangi M, Anvari E, Ghalamfarsa G, Mohammadi H, et al. Adenosine and adenosine receptors in the immunopathogenesis and treatment of cancer. Journal of Cellular Physiology. 2018; 233(3): 2032-57. [View at Publisher] [DOI:10.1002/jcp.25873] [PubMed] [Google Scholar]
8. Li Y, Zhu Z, Hou X, Sun Y. LncRNA AFAP1-AS1 Promotes the Progression of Colorectal Cancer through miR-195-5p and WISP1. J Oncol. 2021:6242798. [View at Publisher] [DOI:10.1155/2021/6242798] [PubMed] [Google Scholar]
9. Mousavi S, Panjehpour M, Izadpanahi MH, Aghaei M. Expression of adenosine receptor subclasses in malignant and adjacent normal human prostate tissues. The Prostate. 2015; 75(7): 735-47. [View at Publisher] [DOI:10.1002/pros.22955] [PubMed] [Google Scholar]
10. Hajizadeh F, Masjedi A, Asl SH, Kiani FK, Peydaveisi M, Ghalamfarsa G, et al. Adenosine and adenosine receptors in colorectal cancer. International immunopharmacology. 2020; 87: 106853. [View at Publisher] [DOI:10.1016/j.intimp.2020.106853] [PubMed] [Google Scholar]
11. Dhalla AK, Shryock JC, Shreeniwas R, Belardinelli L. Pharmacology and therapeutic applications of A1 adenosine receptor ligands. Current topics in medicinal chemistry. 2003; 3(4): 369-85. [View at Publisher] [DOI:10.2174/1568026033392246] [PubMed] [Google Scholar]
12. Klotz K-N, Hessling J, Hegler J, Owman C, Kull B, Fredholm B, et al. Comparative pharmacology of human adenosine receptor subtypes-characterization of stably transfected receptors in CHO cells. Naunyn-Schmiedeberg's archives of pharmacology. 1997;357(1):1-9. [View at Publisher] [DOI:10.1007/PL00005131] [PubMed] [Google Scholar]
13. Auchampach JA. Adenosine receptors and angiogenesis. Circulation research. 2007;101(11):1075-7. [View at Publisher] [DOI:10.1161/CIRCRESAHA.107.165761] [PubMed]
14. Liu Z, Yan S, Wang J, Xu Y, Wang Y, Zhang S, et al. Endothelial adenosine A2a receptor-mediated glycolysis is essential for pathological retinal angiogenesis. Nature communications. 2017; 8(1): 1-18. [View at Publisher] [DOI:10.1038/s41467-017-00551-2] [PubMed] [Google Scholar]
15. Di Iorio P, Caciagli F, Giuliani P, Ballerini P, Ciccarelli R, Sperling O, et al. Purine nucleosides protect injured neurons and stimulate neuronal regeneration by intracellular and membrane receptor‐mediated mechanisms. Drug development research. 2001; 52(1‐2): 303-15. [View at Publisher] [DOI:10.1002/ddr.1128] [Google Scholar]
16. Effendi WI, Nagano T, Kobayashi K, Nishimura Y. Focusing on adenosine receptors as a potential targeted therapy in human diseases. Cells. 2020;9(3):785. [View at Publisher] [DOI:10.3390/cells9030785] [PubMed] [Google Scholar]
17. Mediavilla-Varela M, Luddy K, Noyes D, Khalil FK, Neuger AM, Soliman H, et al. Antagonism of adenosine A2A receptor expressed by lung adenocarcinoma tumor cells and cancer associated fibroblasts inhibits their growth. Cancer biology & therapy. 2013;14(9):860-8. [View at Publisher] [DOI:10.4161/cbt.25643] [PubMed] [Google Scholar]
18. Beavis PA, Divisekera U, Paget C, Chow MT, John LB, Devaud C, et al. Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors. Proceedings of the National Academy of Sciences. 2013; 110(36): 14711-6. [View at Publisher] [DOI:10.1073/pnas.1308209110] [PubMed] [Google Scholar]
19. Gessi S, Bencivenni S, Battistello E, Vincenzi F, Colotta V, Catarzi D, et al. Inhibition of A2A adenosine receptor signaling in cancer cells proliferation by the novel antagonist TP455. Frontiers in pharmacology. 2017;8:888. [View at Publisher] [DOI:10.3389/fphar.2017.00888] [PubMed] [Google Scholar]
20. Palani CD, Ramanathapuram L, Lam-Ubol A, Kurago ZB. Toll-like receptor 2 induces adenosine receptor A2a and promotes human squamous carcinoma cell growth via extracellular signal regulated kinases ½. Oncotarget. 2018; 9(6): 6814. [View at Publisher] [DOI:10.18632/oncotarget.23784] [PubMed] [Google Scholar]
21. Tamura K, Kanno T, Fujita Y, Gotoh A, Nakano T, Nishizaki T. A2a adenosine receptor mediates HepG2 cell apoptosis by downregulating Bcl‐XL expression and upregulating bid expression. Journal of cellular biochemistry. 2012; 113(5): 1766-75. [View at Publisher] [DOI:10.1002/jcb.24048] [PubMed] [Google Scholar]

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2007 All Rights Reserved | Medical Laboratory Journal

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.